
Our Team
BRIM Biotechnology brings together experts across science, engineering, and technology disciplines to deliver a more efficient, less costly, drug development process. Our talented team has forged decades worth of strong global connections and experience. We operate based on a virtual biotechnology model, integrating our expert R&D operation team in Taiwan with our skilled overseas scientific team. We have years of experience working in technological and pharmaceutical development, regulatory affairs, and marketing and IP, with expertise across the field of innovative drug development, including pre-clinical toxicology, clinical pharmacology, and management. We harness the power of our team’s expertise in translational science to deliver a difference for patients.

Translational Science Expertise
Leadership Team
Wen Chyi Shyu, PhD
CEO
With more than three decades of experience working in the life sciences industry, Wen Chyi Shyu has a unique combination of technical and management expertise. She has served in a range of global leadership roles for some of the world′s top pharmaceutical companies, including Bristol Myers Squibb and Takeda Pharmaceutical Company. Her experience in drug metabolism to pharmacokinetics (DMPK) ranges from pre-clinical research discovery to clinical drug development and extended to life cycle management. She has authored over 100 scientific publications, been responsible for more than 100 IND submissions, and led NDA/BLA/MAA/SNDA registrations of more than 15 drugs, including maribavir, dapagliflozin, brentuximab vedotin, and vedolizumab.Wen Chyi brings to BRIM extensive industry experience and a passion for driving innovation in the drug discovery and development process. She is on the leadership team of the Drug Metabolism Technical Group (DMTG) and is on the Steering Committee and Treasury of the New England Drug Metabolism Discussion Group (NEDMDG) to identify and improve the drug discovery process and to shorten the study turnaround time.Wen Chyi has a passion for developing people. Through training and motivation, research scientists can be developed into successful pharmaceutical executives to build international and multi-disciplinary teams. She, as an example, has also established and led numerous cross-functional teams to effectively integrate metabolism, pharmacokinetics, pharmaceutics, and drug safety into drug discovery and development.Wen Chyi holds a Bachelor of Science from the School of Pharmacy at Taipei Medical College and a PhD from the College of Pharmacy at the University of Connecticut, USA. She is also a Post-Doctoral Fellow at the University of Florida.
Haishan Jang, PhD, MBA
Vice Chairman, CGS (Chief Global Strategist)
Dr Haishan Jang has over 30 years of experience in the pharmaceutical industry. Prior to forming BRIM, she worked at Sterling Winthrop (Kodak), Sanofi, DuPont, and Centocor (J&J), where she was the Senior Director of Biologics Clinical Pharmacology. Haishan’s extensive experience across the entire drug discovery process, from research through to clinical translation and commercial development, has given her the unique ability to understand the driving factors needed across all parts of a business to deliver world-class, life-changing innovation.Driven by her own need for continued learning, Haishan is passionate about developing and supporting young scientists in Taiwan – driving BRIM′s corporate mission to inspire and nurture the next generation of biotech entrepreneurs and innovators to bring sustainable and affordable healthcare to everyone.Haishan has a PhD in Physical Chemistry and an MBA from Temple University, Pennsylvania.
Frank W. Lee, PhD
CSO
Dr Frank Lee has over four decades of R&D experience working in drug metabolism and pharmacokinetics (DMPK), drug candidate selection, and first-in-human (FIH) clinical trials strategy for some of the world′s largest pharmaceutical companies, including Syntex, Glaxo, Dupont, Millennium, and Takeda. During his career, Frank has participated in the development of several brand-name drugs such as Naprosyn®, Anaprox®, and Ticlid®. Prior to his retirement in 2012, he held the position of VP of DMPK at Takeda, where he oversaw DMPK and participated in the drug candidate selection and FIH strategy.In addition to holding a Board position at BRIM, Frank sits on the board at Foresee Pharmaceuticals in Taiwan. He is passionate about putting Taiwanese biotech companies on the global stage and believes that pioneering research and advanced technologies are the keys to discovering new medicines for urgent, unmet medical needs.Frank has a PhD in Medicinal Chemistry from the University of California, San Francisco.
Senior Scientific Team